SGLT-2 inhibitors were shown to improve parameters of arterial stiffness, such as reduction of central systolic blood pressure, central pulse pressure [57,58], pulse wave velocity [46,52] and augmentation index [59] in patients with diabetes. Here, SLC5A2 is linked to diabetes mellitus.